Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralf Ewert

Showing results (21-30 of 239) with videos related to

Pageof 24
Sort By:
American Heart Journal|June 2, 2007
Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprostBirger Wolff, Sven Lodziewski, Tom Bollmann, et al.
Respiratory Medicine|March 1, 2021
Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and futureBeate Stubbe, Christian F Opitz, Michael Halank, et al.
Expert Opinion on Pharmacotherapy|August 12, 2009
Inhalative iloprost - pharmacology and clinical applicationRalf Ewert, Christoph Schäper, Michael Halank, et al.
Expert Review of Respiratory Medicine|November 30, 2021
Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertensionRalf Ewert, Dirk Habedank, Michael Halank, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 13, 2008
Diffuse alveolar hemorrhage with acute respiratory distress syndrome associated with phenprocoumon therapyAnne F Klenner, Sigrun Friesecke, Christoph Schäper, et al.
Radiology|December 4, 2002
Bronchiolitis obliterans syndrome in lung transplant recipients: use of spirometrically gated CTFriedrich D Knollmann, Ralf Ewert, Tarja Wündrich, et al.
Therapeutic Advances in Respiratory Disease|August 24, 2019
Practical management of riociguat in patients with pulmonary arterial hypertensionMichael Halank, Kristin Tausche, Ekkehard Grünig, et al.
BMC Pulmonary Medicine|March 29, 2023
Primary mitochondrial disease as a rare cause of unclear breathlessness and distinctive performance degradation - a case reportRalf Ewert, Mohamed A Elhadad, Dirk Habedank, et al.
Pneumologie (Stuttgart, Germany)|June 27, 2003
[Sildenafil in pulmonary hypertension]Ralf Ewert, Marius Höper, Michael Halank, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|January 9, 2019
Predictive Capability of Cardiopulmonary and Exercise Parameters From Day 1 to 6 Months After Acute Pulmonary EmbolismDirk Habedank, Christian Opitz, Tim Karhausen, et al.
Pageof 24

Showing results (21-30 of 239) with videos related to

Sort By:
Pageof 24
American Heart Journal|June 2, 2007
Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprostBirger Wolff, Sven Lodziewski, Tom Bollmann, et al.
Respiratory Medicine|March 1, 2021
Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and futureBeate Stubbe, Christian F Opitz, Michael Halank, et al.
Expert Opinion on Pharmacotherapy|August 12, 2009
Inhalative iloprost - pharmacology and clinical applicationRalf Ewert, Christoph Schäper, Michael Halank, et al.
Expert Review of Respiratory Medicine|November 30, 2021
Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertensionRalf Ewert, Dirk Habedank, Michael Halank, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 13, 2008
Diffuse alveolar hemorrhage with acute respiratory distress syndrome associated with phenprocoumon therapyAnne F Klenner, Sigrun Friesecke, Christoph Schäper, et al.
Radiology|December 4, 2002
Bronchiolitis obliterans syndrome in lung transplant recipients: use of spirometrically gated CTFriedrich D Knollmann, Ralf Ewert, Tarja Wündrich, et al.
Therapeutic Advances in Respiratory Disease|August 24, 2019
Practical management of riociguat in patients with pulmonary arterial hypertensionMichael Halank, Kristin Tausche, Ekkehard Grünig, et al.
BMC Pulmonary Medicine|March 29, 2023
Primary mitochondrial disease as a rare cause of unclear breathlessness and distinctive performance degradation - a case reportRalf Ewert, Mohamed A Elhadad, Dirk Habedank, et al.
Pneumologie (Stuttgart, Germany)|June 27, 2003
[Sildenafil in pulmonary hypertension]Ralf Ewert, Marius Höper, Michael Halank, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|January 9, 2019
Predictive Capability of Cardiopulmonary and Exercise Parameters From Day 1 to 6 Months After Acute Pulmonary EmbolismDirk Habedank, Christian Opitz, Tim Karhausen, et al.
Pageof 24